ストックスクリーナーアプリを入手
25.64
3.35%
-0.89
前日終値:
$26.53
開ける：
$26.35
24時間の取引高:
148.56K
Relative Volume:
0.85
時価総額：
$730.71M
収益：
-
当期純損益:
$-69.47M
株価収益率:
-4.5808
EPS:
-5.5973
ネットキャッシュフロー:
$-73.92M
1週間 パフォーマンス:
-3.21%
1か月 パフォーマンス:
+20.43%
6か月 パフォーマンス:
+6.66%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$25.43
$27.77
1週間の範囲:
$25.17
$27.89
52週間の値動き範囲:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
名前
Lenz Therapeutics Inc
セクター
電話
858-925-7000
住所
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
LENZ を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
25.64 | 730.71M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-18 | 開始されました | TD Cowen | Buy |
| 2024-09-27 | 開始されました | Raymond James | Outperform |
| 2024-08-12 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-15 | 開始されました | Leerink Partners | Outperform |
| 2024-04-15 | 開始されました | William Blair | Outperform |
| 2024-04-10 | 開始されました | Citigroup | Buy |
| 2024-03-27 | 開始されました | Piper Sandler | Overweight |
| 2023-02-23 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2023-02-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-02-23 | ダウングレード | Cowen | Outperform → Market Perform |
| 2023-01-25 | ダウングレード | BTIG Research | Buy → Neutral |
| 2023-01-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-06 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-06 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-14 | 開始されました | BTIG Research | Buy |
| 2022-03-22 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-02-18 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-07-20 | 開始されました | Morgan Stanley | Overweight |
| 2021-07-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Lenz Therapeutics Inc (LENZ) 最新ニュース
LENZ Therapeutics Stock Is Attractive Before PDUFA (NASDAQ:LENZ) - Seeking Alpha
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Bank of New York Mellon Corp Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Brokers Issue Forecasts for LENZ Q2 Earnings - Defense World
What is Leerink Partnrs’ Forecast for LENZ Q1 Earnings? - Defense World
William Blair Issues Negative Outlook for LENZ Earnings - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Price Target Raised to $47.00 - Defense World
Equities Analysts Offer Predictions for LENZ FY2026 Earnings - Defense World
What is HC Wainwright’s Estimate for LENZ Q1 Earnings? - Defense World
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook - TipRanks
Promising Outlook for LENZ Therapeutics: Buy Rating Affirmed Amid Strong Market Position and Upcoming Product Launch - TipRanks
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World
Citi raises LENZ Therapeutics price target to $47, keeps Buy rating - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism By Investing.com - Investing.com Australia
LENZ Therapeutics stock holds $38 target on FDA approval optimism - Investing.com
Citi ups PT on LENZ Therapeutics on eye-drop approval confidence - TradingView
Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress - MSN
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive - Investing.com India
Earnings call transcript: LENZ Therapeutics Q4 2024 shows innovation drive By Investing.com - Investing.com UK
LENZ Therapeutics, Inc. SEC 10-K Report - TradingView
LENZ THERAPEUTICS Earnings Results: $LENZ Reports Quarterly Earnings - Nasdaq
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - The Manila Times
LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent ... - The Bakersfield Californian
LENZ Therapeutics Secures FDA Decision Date with $209M War Chest for Presbyopia Drug Launch - StockTitan
LENZ Therapeutics (NASDAQ:LENZ) Now Covered by TD Cowen - Defense World
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target - Investing.com Canada
TD Cowen lifts LENZ Therapeutics stock to buy, sets $60 target By Investing.com - Investing.com South Africa
TD Cowen Initiates LENZ Therapeutics at Buy With $60 Price Target -March 18, 2025 at 07:09 am EDT - Marketscreener.com
American Electric Power, Block and Lenz Therapeutics - TradingView
LENZ THERAPEUTICS Earnings Preview: Recent $LENZ Insider Trading, Hedge Fund Activity, and More - Nasdaq
LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 - The Manila Times
LENZ Therapeutics Q4 Earnings: Key Updates Coming on Presbyopia Eye Drops - StockTitan
Rhumbline Advisers Boosts Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics to Host Commercial Day on April 15, 2025 - The Manila Times
Will LENZ's Presbyopia Eye Drop Disrupt the Vision Care Market? Commercial Strategy Reveal Coming - StockTitan
Insiders Enjoy US$227k Return After Buying LENZ Therapeutics Stock - Simply Wall St
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at Upcoming Investor Conferences in March 2025 - Nasdaq
Can LENZ's Novel Presbyopia Treatment Disrupt the $8B Eye Care Market? Key Investor Presentations Coming - StockTitan
Myopia And Presbyopia Eye Drops Market Future Business - openPR
LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - Defense World
LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k - Yahoo Finance UK
Citi maintains Buy on LENZ Therapeutics, target at $44 By Investing.com - Investing.com Canada
Citi maintains Buy on LENZ Therapeutics, target at $44 - Investing.com
Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World
916 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World
LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.7%Should You Sell? - MarketBeat
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by SG Americas Securities LLC - Defense World
Analysts Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Armenian Reporter
Lenz Therapeutics Inc (LENZ) 財務データ
収益
当期純利益
現金流量
EPS
Lenz Therapeutics Inc (LENZ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Olsson Shawn | Chief Commercial Officer |
Dec 16 '24 |
Option Exercise |
2.08 |
3,333 |
6,933 |
3,333 |
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):